Skip to content

Cerevance

  • Platform
  • Tissue Collection
  • Pipeline
  • Team
    • Leadership
    • Advisors
    • Board
    • Investors
  • News
    • Press Releases
    • Media Coverage
  • Contact

News

Press Releases

December 8, 2020

Cerevance Appoints David Lubner to Board of Directors

November 16, 2020

Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study

July 21, 2020

Cerevance Expands Series B Financing to $65 Million

April 14, 2020

Cerevance Closes $45 Million Series B Financing

January 7, 2020

Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors

December 17, 2019

Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders

December 4, 2019

Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease

June 3, 2019

Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor

April 30, 2019

Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424

April 16, 2019

Cerevance Appoints Industry Veteran Roland Bürli, Ph.D. as Vice President of Drug Discovery

  • 1
  • 2
  • 3

View Media Coverage

Cerevance
  • Platform
  • Tissue Collection
  • Pipeline
  • Team
  • News
  • Contact
Copyright Cerevance 2021